UnknownNot Applicable

Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms

Egypt100 participantsStarted 2022-12-15

Plain-language summary

In around 90% of the patients with MPNs, an acquired mutation that promotes JAK/STAT signaling is identified \[3, 4\]. The JAK/STAT pathway transduces signals from cytokines including erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor.24 A point mutation that activates JAK2, JAK2V617F, is present in around 95% of patients with PV and 40% to 60% of patients with ET and MF

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients aged 18 years and older who were newly diagnosed to have Philadelphia negative myeloproliferative neoplasms between September 2014 and November 2022 at Sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic. Exclusion Criteria: * Patients were excluded if: (1) their disease of thrombocytosis or polycythemia was determined to be reactive, (2) their disease was not newly diagnosed, (3) their disease met WHO criteria for chronic or acute myeloid leukemia.

What they're measuring

Neutrophil-Lymphocyte Ratio in Patients with Philadelphia Negative Myeloproliferative Neoplasms

Timeframe: baseline

Carotid Plaque Burden in Patients with Philadelphia Negative Myeloproliferative Neoplasms

Timeframe: baseline

Trial details

NCT IDNCT05993052

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-08

Contact for this trial

Mahmoud Gaber, dr

+201007399833 mahmoudgaber@med.sohag.edu.eg

View on ClinicalTrials.gov More Myeloproliferative Neoplasm trials